Jefferies’ team of analysts have recently been touting Roche as their favourite big European pharma – but going into 2020 it’s Novartis that gets the strongest “buy” rating in a broker note
It’s nearly always bad news when pharma companies provide an “update” about a trial – and the statement today from Novartis about its asthma drug fevipiprant must make bleak reading for all
Gilead’s Kite unit plans to file its latest CAR-T therapy on the basis of a new study showing some impressive response rates in patients with relapsed or refractory mantle cell lymphoma.